Other Events ·
ANVISA grants marketing authorization for generic semaglutide injection in Brazil
RDYDR Reddys Laboratories Ltd
Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for Dr. Reddy’s Laboratories’ generic semaglutide injection to treat adults with insufficiently controlled type 2 diabetes mellitus. The product will be available as a pre-filled, multi-dose injectable pen in two presentations for once-weekly dosing. Brazil ranks sixth globally in the number of adults living with diabetes, and the local semaglutide market is estimated at approximately USD 244.6 million. Dr. Reddy’s plans to launch the product in partnership with Aché. Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, offering APIs, generics, biosimilars and OTC products.